Thank you for subscribing!
Learn More about Next Investors - Experts in Biotech Stocks
Next Investors Archived Dec 03, 2019
Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.
Next Investors Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Get expert stock analysis direct in your inbox
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Next Investors Archived Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
Next Investors Archived Jul 02, 2019
Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?
Next Investors Archived May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Next Investors Archived Apr 08, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
Next Investors Archived Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Next Investors Archived Dec 17, 2018
Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.
Next Investors Archived Nov 13, 2018
Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.
Next Investors Archived Oct 30, 2018
Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.
Next Investors Archived Oct 18, 2018
This week, Canada has become the second country in the world — and the first industrialised nation — to legalise recreational cannabis use nationwide. ASX cannabis innovator, Creso Pharma (ASX:CPH), has welcomed this change with open arms.
Next Investors Archived Oct 16, 2018
Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.
Next Investors Archived Sep 05, 2018
Creso Pharma (ASX:CPH) is one step closer to launching its range of cannabis infused products.
Next Investors Archived Jul 17, 2018
Immuron Limited (ASX:IMC | NASDAQ:IMRN) has provided a steady stream of positive news across its microbiome immunotherapy platform — which includes assets that are preclinical, at clinical stage, and the already on-the-market Travelan® product.
Next Investors Archived Jul 13, 2018
Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.
Join Our Mailing List
